Focal Segmental Glomerulosclerosis
55
16
19
23
Key Insights
Highlights
Success Rate
77% trial completion
Published Results
12 trials with published results (22%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
12.7%
7 terminated out of 55 trials
76.7%
-9.9% vs benchmark
11%
6 trials in Phase 3/4
52%
12 of 23 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 23 completed trials
Clinical Trials (55)
An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
Genetic Markers for Focal Segmental Glomerulosclerosis
Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis
Genetic Causes of FSGS, Nephrotic Syndrome, or Kidney Failure
NEPTUNE Match Study
Atrasentan in Patients With Proteinuric Glomerular Diseases
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease
Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)
A Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS)
taVNS for FRNS in Children
AMPK-activation by Metformin in FSGS: AMP-FSGS
Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis
PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children